DSM shareholders approve merger with Firmenich at Extraordinary General Meeting of Shareholders; combined company will seek to build a leading creation and innovation partner in nutrition, beauty and well-being

Sample article from our Consumer Wellness

HEERLEN, Netherlands , January 23, 2023 (press release) –

 

DSM shareholders approve DSM-Firmenich merger at Extraordinary General Meeting

Royal DSM, a global purpose-led science-based company, today held an Extraordinary General Meeting of Shareholders (EGM). The DSM Shareholders approved the proposed merger between DSM and Firmenich International SA (Firmenich) and voted in favour of all related resolutions as set out in the notice of the EGM.

Geraldine Matchett and Dimitri de Vreeze, Co-CEOs of DSM, commented: “This is a momentous day in the long history of DSM. We are grateful for our shareholders’ strong support for this merger as we seek to build the leading creation and innovation partner in nutrition, beauty and well-being. There are powerful synergies from bringing together DSM and Firmenich that can deliver superior growth. DSM-Firmenich will be uniquely positioned to best anticipate and address the changing needs of consumers, unlocking new opportunities that benefit our customers, our people, and the wider world.

In accordance with the Offering Circular, the Acceptance Threshold for the Exchange Offer is now automatically adjusted from 95% to 80% of DSM's aggregate issued and outstanding ordinary share capital. DSM and Firmenich continue to work to satisfy all the conditions of the Exchange Offer as set out in the Offering Circular.

As confirmed in the announcement of 23 January 2023, the Acceptance Period, which period was set to expire on 31 January 2023, is extended. The Acceptance Period is extended until two weeks after the announcement that the Indian competition clearance has been obtained, but not before 17:40 hours CET on 7 March 2023 and no later than 17:40 hours CET on 11 April 2023.

At the EGM, 75.92% of the total issued and outstanding share capital of DSM was represented. The Transactions were approved by approximately 99.86% of the votes cast. The final voting results from today’s DSM EGM will be published on the transaction website: www.creator-innovator.com/en/offering-circular-and-egm/. Draft minutes of the DSM EGM will be published no later than three months from the date of the EGM on the transaction website as well. 

The information in this press release is not intended to be complete. Details of the exchange offer and the EGM, as well as more information about DSM-Firmenich, can be found at www.creator-innovator.com/en/offering-circular-and-egm/

This is a press release by Koninklijke DSM N.V. (Royal DSM), in connection with the public exchange offer by Danube AG (to be renamed DSM-Firmenich AG) for all the issued and outstanding ordinary shares in the share capital of DSM (the Exchange Offer). This press release contains information within the meaning of Article 7(1) of the European Market Abuse Regulation (596/2014). This press release does not constitute an offer, or any solicitation of any offer, to buy or subscribe for any securities. Any offer will be made only by means of the offering circular dated 22 November 2022 (the Offering Circular) approved by the Dutch Authority for Financial Markets (Stichting Autoriteit Financiële Markten). This press release is not for general release, publication or distribution, in whole or in part, in or into, directly or indirectly, the United States or any other jurisdiction where such release, publication or distribution would violate applicable laws or regulations. Capitalized terms used but not defined in this press release will have the meaning as set forth in the Offering Circular.

For more information

Gareth Mead

DSM Media Relations
tel. +31 (0) 45 5782420

Dave Huizing

DSM Investor Relations
tel. +31 (0) 45 5782864

* All content is copyrighted by Industry Intelligence, or the original respective author or source. You may not recirculate, redistrubte or publish the analysis and presentation included in the service without Industry Intelligence's prior written consent. Please review our terms of use.

See our dashboard in action - schedule an demo
Dan Rivard
Dan Rivard
- VP Market Development -

We offer built-to-order consumer wellness coverage for our clients. Contact us for a free consultation.

About Us

We deliver market news & information relevant to your business.

We monitor all your market drivers.

We aggregate, curate, filter and map your specific needs.

We deliver the right information to the right person at the right time.

Our Contacts

1990 S Bundy Dr. Suite #380,
Los Angeles, CA 90025

+1 (310) 553 0008

About Cookies On This Site

We collect data, including through use of cookies and similar technology ("cookies") that enchance the online experience. By clicking "I agree", you agree to our cookies, agree to bound by our Terms of Use, and acknowledge our Privacy Policy. For more information on our data practices and how to exercise your privacy rights, please see our Privacy Policy.